ランキング価格はじめての方へ
  1. 米国企業
  2. Cerevel Therapeutics Holdings, Inc.

Cerevel Therapeutics Holdings, Inc.CERE

時価総額
$81.1億
PER
サマリーテーブルに戻る
損益計算書バランスシートキャッシュフロー
2020年
12月31日		2021年
12月31日		2022年
12月31日
Net loss-152-225-352
Depreciation and amortization035
Adjustments to operating lease expense-11
Equity-based compensation112439
Change in Fair Value of Financing Liability-2-7
Fair Value Adjustment of Warrants-4-
Non-cash interest expense--1
Amortization of premiums and accretion of discounts on marketable securities--7
Other non-cash items--0-0
Prepaid expenses and other current assets-051
Other assets111
Accounts payable17-1
Accrued expenses and other liabilities--31
Operating lease liability76-
Net cash flows used in operating activities-118-179-293
Purchases of marketable securities-425888
Maturities and redemptions of marketable securities--503
Purchases of property and equipment19114
Net cash flows used in investing activities-19-436-389
Proceeds from issuance of common stock related to follow-on offering, net of offering costs-328238
Proceeds From Business Combination Transaction Net Of Offering Costs--0-
Proceeds from Warrant Exercises-55-
Proceeds from the exercise of stock options and ESPP purchases--13
Proceeds from Related Party Debt-1619
Proceeds from financing liability-1619
Proceeds from Convertible Debt--335
Deferred costs related to financing activities-00
Net cash flows provided by financing activities441424623
Net increase (decrease) in cash, cash equivalents, and restricted cash304-191-59
Capital Expenditures Incurred but Not yet Paid--0
Offering costs included in accounts payable and other current liabilities--0
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability0--
Cashless exercise of private placement warrants-4-
Settlement Of Equity Commitment Liability Upon Issuance Of Series A1 Preferred Stock And Series A Common Stock6--
Reclassification of deferred financing costs to additional paid-in capital--0